Want to see JP:2183 full AI Analyst Report?
Linical Co., Ltd. (2183) AI Stock Analysis
Linical Co., Ltd.
(TSE/TYO:2183)
The overall score is critically low, driven primarily by severe financial deterioration including collapsing revenues, deeply negative margins, and significant cash burn. The negative P/E and likely unsustainable dividend further weaken the investment case. Technicals confirm a persistent downtrend, offering no counterbalance to the fundamental risks.
Linical Co., Ltd. (2183) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.52B
- Dividend Yield
- 4.00%
- Average Volume (3M)
- 47.66K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.67
- Revenue Growth
- -21.55%
- EPS Growth
- -497.97%
- Country
- Japan
- Employees
- 577
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Linical Co., Ltd. Business Overview & Revenue Model
Company Description
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in deve...
How the Company Makes Money
Linical primarily makes money by providing fee-based CRO services to sponsors (e.g., pharmaceutical and biotech companies) that outsource clinical development work. Revenue is typically generated through service contracts tied to specific clinical de...
Linical Co., Ltd. Financial Statement Overview
Summary
Severe financial distress. Revenue declined 14.5% to ¥8.7B with gross margin collapsing to 8.7%. Net loss of ¥3.33B (-38.4% margin). Operating cash flow turned deeply negative (-¥1.52B) and equity halved to ¥3.98B. The company is burning cash with no immediate signs of reversal.
Income Statement
15Very NegativeBalance Sheet
25NegativeCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.95B | 8.67B | 10.44B | 12.31B | 12.52B | 11.56B |
| Gross Profit | 119.13M | 753.13M | 2.01B | 3.43B | 3.84B | 3.34B |
| EBITDA | -2.21B | -1.54B | -46.50M | 1.25B | 1.76B | 1.54B |
| Net Income | -3.79B | -3.33B | -539.10M | 338.27M | 1.00B | 790.49M |
Balance Sheet | ||||||
| Total Assets | 11.06B | 12.00B | 16.78B | 18.54B | 17.46B | 15.72B |
| Cash, Cash Equivalents and Short-Term Investments | 4.68B | 5.20B | 7.04B | 7.47B | 7.04B | 5.99B |
| Total Debt | 2.04B | 2.25B | 2.42B | 3.00B | 3.63B | 4.19B |
| Total Liabilities | 7.85B | 8.02B | 9.52B | 10.30B | 9.88B | 9.17B |
| Stockholders Equity | 3.21B | 3.98B | 7.25B | 8.24B | 7.58B | 6.54B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.55B | 602.21M | 1.08B | 1.85B | 1.64B |
| Operating Cash Flow | 0 | -1.52B | 605.10M | 1.11B | 1.86B | 1.68B |
| Investing Cash Flow | 0 | -1.96M | -54.93M | -70.47M | -31.79M | -32.14M |
| Financing Cash Flow | 0 | -513.25M | -939.22M | -960.92M | -957.33M | -951.55M |
Linical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2183, the sentiment is Negative. The current price of 198.00 is below the 20-day moving average (MA) of 201.10, below the 50-day MA of 203.60, and below the 200-day MA of 239.97, indicating a bearish trend. The MACD of -1.12 indicates Positive momentum. The RSI at 44.94 is Neutral, neither overbought nor oversold. The STOCH value of 15.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2183.
Linical Co., Ltd. Peers Comparison
Overall Rating
JP:489156Neutral
JP:234250Neutral
JP:237045Neutral
JP:497845Neutral- JP:218340Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4891 | 56Neutral | JPY 6.54B | -6.22 | ― | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:2342 | 50Neutral | JPY 3.63B | 112.09 | ― | ― | 2.37% | ― |
| JP:2370 | 45Neutral | JPY 5.69B | -4.93 | ― | ― | 12.73% | 25.71% |
| JP:4978 | 45Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:2183 | 40Underperform | JPY 4.52B | -1.19 | ― | 4.00% | -21.55% | -497.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2183 | Linical Co., Ltd. | 200.00 | -135.63 | -40.41% | |
| JP:2342 | Trans Genic Inc. | 215.00 | 24.00 | 12.57% | |
| JP:2370 | MEDINET Co., Ltd. | 20.00 | -14.00 | -41.18% | |
| JP:4891 | TMS Co., Ltd. | 135.00 | -4.00 | -2.88% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% |
Linical Co., Ltd. Corporate Events
Linical’s Quarterly Loss Widens as Sales Drop in Japan, U.S. and Europe
Linical Co., Ltd., a Japan-based contract research organization, offers clinical trial and development services to pharmaceutical and biotech companies across Japan, the U.S., Europe, Korea and Taiwan. Its revenues are driven by the volume and profit...
Linical Posts Deeper Quarterly Loss but Keeps Full-Year Outlook and Dividend Plan
Linical reported a sharp deterioration in results for the three months to June 30, 2026, with net sales down 27.2% year-on-year to ¥1,912 million and a quarterly loss attributable to owners of parent of ¥636 million. Net income per share fe...
Linical Records Dividend Income from Korean Subsidiary
Linical Co., Ltd., a Japan-based contract research organization serving pharmaceutical and biotechnology companies, operates an international network of subsidiaries including LINICAL KOREA CO., LTD. This structure supports its focus on global clinic...
Linical Releases FY2026 Results and Sets Outlook for FY2027
Linical Co., Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2026, outlining performance over the period and giving investors a structured view of its recent business trends. The release also presented forecasts f...
Linical Cuts Year-End Dividend in Shift Toward Profit Recovery and Cash Discipline
Linical Co., Ltd. has approved a year-end dividend of JPY 8.00 per share for the fiscal year ended March 31, 2026, with a total payout of about JPY 180.7 million and an effective payment date of June 9, 2026. The dividend matches the latest forecast...
Linical Lifts Hard Backlog to ¥13.0 Billion on New Contract Wins
Linical Co., Ltd. reported updated hard backlog figures following the completion of two projects that had previously been in contract execution procedures. The company’s hard backlog, representing contracted sales to be realized over the next s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 18, 2026